English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Ependymoma represents the third most common childhood malignancy of the brain, accounting for approximately 10% of all pediatric brain malignancies. The most common site of presentation is the posterior fossa. Standard therapy involves maximal safe resection, followed by radiation therapy (RT). The benefit of chemotherapy (CHT) has not been demonstrated and remains under investigation. Molecular analysis has identified 2 groups within ependymomas of the posterior fossa (PF-EPN) with distinct prognoses and characteristics (Table 1): group A (PF-EPN-A) and group B (PFEPN-B). Grouping is prognostic, but World Health Organization (WHO) II versus III grade designation is not reliably prognostic. Therefore, current consensus guidelines recommend that treatment decisions not be

Anaplastic Ependymoma and Posterior Fossa Grouping in a Patient With H3K27ME3 Loss of Expression but Chromosomal Imbalance